

# Clostridioides difficile infection (CDI)



# Microorganism

- Clostridioides difficile (formerly Clostridium difficile), a Gram-positive, spore-forming bacillus.
- *C. difficile* is one of the leading causes of diarrhea in hospitalized or outpatient individuals who have received or received antibiotic therapy.
- Only toxigenic strains that produce toxins A and B are pathogenic.

## Infection or Asymptomatic Carriage?

Asymptomatic carriage is common	C. difficile testing should not be performed in
<ul> <li>Less than 3% in the general population</li> </ul>	<ul> <li>Children under 3 years of age</li> </ul>
Up to 30% in hospitalized patients	Asymptomatic individuals
<ul> <li>Up to 50% in children under 1 year of age</li> </ul>	<ul> <li>Patients who have clinically recovered from</li> </ul>
• Up to 25% following a <i>C. difficile</i> infection	a <i>C. difficile</i> infection

#### **Manifestations**

Typical form	Severe form (≥ 1 criteria)	Possible complications
<ul> <li>Profuse, watery</li> </ul>	• Fever > 38,5°C	Toxic megacolon
diarrhea	<ul> <li>Leukocytois &gt; 15 x 10<sup>9</sup>/L</li> </ul>	Gastrointestinal perforation
	<ul> <li>Créatinine &gt; 50% above baseline</li> </ul>	• Ileus
	<ul> <li>Imaging findings: colonic distension,</li> </ul>	Septic shock
	colonic wall thickening, or pericolonic	<ul> <li>Arterial hypotension</li> </ul>
	fat stranding	


# Risk Factors for Clostridioides difficile Infection (CDI) and Recurrence

- Antibiotic use within the past 3 months or continuation of antibiotics following a CDI episode
- Age > 65 years
- Recent hospitalization within the past 3 months or prolonged hospital stay
- History of *C. difficile* infection
- Use of proton pump inhibitors
- Comorbidities such as malignancy, immunosuppression, or renal failure

# Diagnostic

Diagnosis is based on microbiological testing

- Performed on diarrheic stool samples (taking the shape of the container)
- To detect the following:
  - **Glutamate dehydrogenase (GDH):** an enzyme specific to *C. difficile*, indicating the presence of the bacterium
  - Free C. difficile toxin, via rapid test or immunoassay: indicates a toxigenic strain and confirms active CDI
  - Toxin gene by PCR: detects the presence of the gene encoding the toxins, indicating a toxigenic strain, but does not confirm actual toxin production, or may reflect low-level expression
- Culture is not routinely performed due to its low sensitivity and prolonged turnaround time



Eric Farfour ( www.clin92.com





# Clostridioides difficile infection (CDI)



#### **Treatment (2021 ESCMID European Guidelines)**

- Discontinue predisposing factors when possible: antibiotics, proton pump inhibitors
- Symptomatic treatment: rehydration
- Contraindicated: antiperistaltic agents (e.g., loperamide)
- Metronidazole is no longer recommended for the treatment of CDI, except in cases where fidaxomicin and vancomycin are unavailable or contraindicated





	Standard Fidaxomicin	200 mg orally twice daily $ ightarrow$ 10 days	1
	Pulsed Fidaxomicine	200 mg orally twice daily $ ightarrow$ 5 days then once every 48 h $ ightarrow$ 18 days	Ī
sage	Vancomycine 125 mg orally four times daily $\rightarrow$ 10 days		
Josa	Pulsed Vancomycine	125 mg orally: 4 times daily $\rightarrow$ 14d, then twice daily $\rightarrow$ 7d, then once daily $\rightarrow$ 7d, then every 48 h $\rightarrow$ 7d, then every 72 h $\rightarrow$ 7d	
	Bezlotoxumab 10 mg/kg intravenously over 1 hour (caution advised in cases of heart failure)		1
	Tigécycline	Loading dose of 100 mg IV, followed by 50 mg IV twice daily	

Fidaxomicin and vancomycin are subject to hospital-only prescription. They are dispensed exclusively through hospital pharmacies and via retrocession

www.clin



# Clostridioides difficile infection (CDI)



# Assessment of Treatment Efficacy

- Evaluation of therapeutic response should be based solely on clinical criteria
- Symptomatic improvement may be gradual and can take up to 72 hours
- Routine microbiological testing for *Clostridioides difficile* is not recommended for follow-up, as asymptomatic carriage is common post-infection

# **Precautionary measures**

- The ability of *Clostridioides difficile* to form spores confers:
  - Resistance to standard disinfectants
  - Resistance to alcohol-based hand sanitizers
  - The capacity to persist in the environment, thereby facilitating transmission
- The following precautions are recommended:

In the hospital setting	Home Management
<ul> <li>Précautions complémentaires contact</li> <li>Implementation of contact precautions</li> <li>Single-patient room placement</li> <li>Hand hygiene using soap and water, followed by alcohol-based hand rub</li> <li>Use of personal protective equipment (e.g., gown, gloves)</li> <li>Enhanced environmental cleaning with sporicidal agents</li> <li>Specific management and disposal of excreta</li> </ul>	<ul> <li>Reinforcement of proper hand hygiene practices</li> <li>No need for isolation measures</li> <li>Recommendation to seek medical attention if diarrhea recurs</li> </ul>